Oxford BioMedica PLC (OXBDF)

[marcusl2]

Very positive day

Biggest thing for me was the trial starting soon (after FDA approval) for CAR T to be used as first line treatment instead of chemo etc. That will really expand the market for us. Cost will come down Doc before you start!

Using both cd19 and BCMA CARS 100% response

patient treated with Car T for prostate cancer

CD33 for AML starting at Penn 2018

Then JD expecting near capacity manuf. and further contracts.